AgomAb Therapeutics (NASDAQ:AGMB) Stock Price Up 9.6% – Time to Buy?

AgomAb Therapeutics NV (NASDAQ:AGMB) shares traded up 9.6% during mid-day trading on Monday . The company traded as high as $15.20 and last traded at $15.13. 40,410 shares were traded during mid-day trading, a decline of 72% from the average session volume of 141,930 shares. The stock had previously closed at $13.81.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. JPMorgan Chase & Co. started coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They issued an “overweight” rating and a $32.00 target price for the company. HC Wainwright assumed coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 price objective for the company. Zacks Research raised AgomAb Therapeutics to a “hold” rating in a research note on Wednesday, March 4th. Leerink Partners started coverage on AgomAb Therapeutics in a report on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 target price for the company. Finally, Morgan Stanley began coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 price target on the stock. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.75.

AgomAb Therapeutics Price Performance

The stock’s 50-day moving average is $11.19.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.